ELAN - MyoKardia Heart Trial And Other News: The Good Bad And Ugly Of Biopharma
MyoKardia reports initiating trial for invasive septal reduction therapy
MyoKardia Inc. (MYOK) announced that it has dosed the first person for the Phase 3 VALOR-HCM clinical trial. The study aims to provide direct clinical evidence of mavacamten’s capability to alleviate the requirement for invasive SRT procedures. The company plans to carry out several studies to evaluate the potential of mavacamten as a backbone therapy for HCM.
VALOR-HCM is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study. It involves patients with symptomatic, obstructive HCM, who meet guideline criteria for septal reduction therapy and have